GlassScriptPhysician profile
Paul D Boyce
NPI 1912988445
$11,856.12
in general payments reported to CMS, 2019-2025
44 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $360 · 2021: $720 · 2022: $3,360 · 2023: $797 · 2024: $4,091 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,809 · Consulting Fee: $2,725 · Education: $90.99 · Travel and Lodging: $42.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.77 |
| Consulting Fee | $2,725.00 |
| Education | $90.99 |
| Travel and Lodging | $42.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $4,053.14 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Sanofi Pasteur INC. | $2,468.60 | 2022 | |
| Glaxosmithkline, LLC. | $791.21 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $678.36 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| United Therapeutics Corporation | $469.35 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Electromed, INC. | $329.50 | 2019-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $327.65 | 2022-2025 | Winrevair |
| Amgen INC. | $267.53 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $252.05 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Bayer Healthcare Pharmaceuticals INC. | $210.78 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $194.53 | 2022-2025 | Dupixent |
| Inari Medical, INC. | $190.69 | 2021-2022 | |
| Verona Pharma, INC. | $177.91 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $152.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2020-2025 | Ofev |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $123.85 | 2023-2025 | Arikayce |
| Genzyme Corporation | $116.60 | 2021-2025 | |
| Mylan Specialty L.P. | $102.00 | 2020-2024 | Yupelri |
| Philips North America LLC | $99.20 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Baxter Healthcare | $91.63 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $87.71 | 2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $64.50 | 2023-2025 | Glassia |
| Abbvie INC. | $48.53 | 2025 | |
| Paratek Pharmaceuticals, INC. | $42.91 | 2019-2024 | Nuzyra |
| Viatris Specialty LLC | $40.05 | 2025 | Yupelri |
| Pfizer INC. | $39.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.51 | 2021 | |
| Ethicon INC. | $34.22 | 2021 | |
| Inogen, INC. | $32.10 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mallinckrodt Hospital Products INC. | $26.77 | 2020 | |
| Horizon Therapeutics Plc | $24.54 | 2019 | |
| Shire North American Group INC | $21.42 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.95 | 2019 | |
| Circassia INC. | $19.27 | 2019 | |
| Phadia US INC. | $18.98 | 2022 | |
| Chiesi USA, INC. | $17.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.56 | 2020 | |
| Sandoz INC. | $14.95 | 2019 | |
| Gilead Sciences, INC. | $14.76 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.